The biomarker testing market size has grown rapidly in recent years. It will grow from $17.51 billion in 2024 to $19.75 billion in 2025 at a compound annual growth rate (CAGR) of 12.8%. The growth during the historic period can be attributed to the rising adoption of personalized medicine, the increased utilization of biomarkers in oncology, the growing prevalence of chronic illnesses, expanded research funding in the life sciences sector, and the heightened demand for early disease detection.
The biomarker testing market size is expected to see rapid growth in the next few years. It will grow to $31.63 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to the expanding application of biomarkers in non-oncology conditions, increasing investments in companion diagnostics, greater integration of artificial intelligence into diagnostic processes, the rising adoption of point-of-care testing, and growing awareness of preventive healthcare. Key trends expected during the forecast period include advancements in sequencing technologies, ongoing innovations in liquid biopsy, progress in multiplex biomarker platforms, breakthroughs in proteomics and metabolomics, and rising investments in research and development.
The rising cancer burden is expected to drive the growth of the biomarker testing market in the coming years. Cancer comprises a group of diseases marked by the uncontrolled growth and spread of abnormal cells. This increasing burden is largely attributed to lifestyle-related risk factors such as unhealthy diets, smoking, physical inactivity, and excessive alcohol consumption. Biomarker testing plays a vital role in cancer detection by enabling early and accurate identification of disease-specific markers, thereby improving diagnostic precision. It also facilitates personalized treatment strategies, resulting in improved patient outcomes and more efficient healthcare management. For instance, in July 2024, the Australian Institute of Health and Welfare reported that 160,570 cancer cases were diagnosed in Australia in 2022, an increase of 3,789 cases from 156,781 in 2021. Therefore, the growing incidence of cancer is contributing significantly to the expansion of the biomarker testing market.
Major companies operating in the biomarker testing market are focusing on developing technologically advanced solutions, such as immunohistochemistry (IHC) technology, to enhance diagnostic accuracy, enable early disease detection, and support personalized treatment strategies. Immunohistochemistry (IHC) is a laboratory technique that utilizes antibodies to detect specific proteins in tissue samples, enabling the identification and visualization of biomarkers critical for disease diagnosis and research. For example, in July 2023, Quest Diagnostics Incorporated, a U.S.-based medical laboratory company, launched a new tissue-based prostate cancer biomarker test through its AmeriPath business. This test leverages proprietary biomarkers EV1, EV2, and EV3 to improve diagnostic precision by helping physicians more accurately identify and distinguish aggressive prostate cancer types. It addresses a critical clinical need by enhancing grading consistency and guiding appropriate, individualized treatment strategies.
In August 2025, Quanterix Corp., a U.S.-based life sciences company, acquired Emission Inc. for approximately $70 million. This acquisition is aimed at expanding Quanterix’s technology portfolio and market presence by incorporating Emission’s advanced multiplex and multi-omic assay technologies. The integration is expected to strengthen Quanterix’s position in the biomarker testing sector, enhance its diagnostic capabilities, and open new market opportunities. Emission Inc. is a U.S.-based biotechnology company specializing in multiplex and multi-omic assay solutions for biomarker testing.
Major players in the biomarker testing market are Roche Diagnostics International Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers AG, Becton Dickinson and Company, GE HealthCare Technologies Inc., Agilent Technologies Inc., Illumina Inc., Hologic Inc., Charles River Laboratories International Inc., PerkinElmer Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Myriad Genetics Inc., Guardant Health Inc., Sino Biological Inc., Proteome Sciences plc.
North America was the largest region in the biomarker testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in biomarker testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the biomarker testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Biomarker testing involves examining blood, tissue, or other bodily fluids to detect specific biological indicators that signify either normal or pathological conditions. This process is vital for disease diagnosis, monitoring disease progression, and creating personalized treatment strategies.
Biomarker testing includes several product types such as consumables, instruments, services, and more. Consumables refer to items that are used and depleted during procedures and must be replenished regularly, including medical supplies, food items, or office essentials. The primary technologies employed are polymerase chain reaction (PCR), next-generation sequencing (NGS), immunoassays, among others. It is widely used in fields such as oncology, cardiology, neurology, and infectious diseases, with key end-users including hospitals, diagnostic labs, research institutions, and other healthcare settings.
The biomarker testing market research report is one of a series of new reports that provides biomarker testing market statistics, including the biomarker testing industry global market size, regional shares, competitors with the biomarker testing market share, detailed biomarker testing market segments, market trends, and opportunities, and any further data you may need to thrive in the biomarker testing industry. These biomarker testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The biomarker testing market consists of revenues earned by entities by providing services such as clinical biomarker testing services, bioinformatics and data analysis services, sample collection and biobanking services, and companion diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The biomarker testing market includes sales of analytical instruments, imaging devices, lab-on-a-chip and microfluidic devices, and data acquisition and integration hardware. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values generated by organizations in the specified geography within the market, irrespective of where they are produced. They do not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The biomarker testing market size is expected to see rapid growth in the next few years. It will grow to $31.63 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to the expanding application of biomarkers in non-oncology conditions, increasing investments in companion diagnostics, greater integration of artificial intelligence into diagnostic processes, the rising adoption of point-of-care testing, and growing awareness of preventive healthcare. Key trends expected during the forecast period include advancements in sequencing technologies, ongoing innovations in liquid biopsy, progress in multiplex biomarker platforms, breakthroughs in proteomics and metabolomics, and rising investments in research and development.
The rising cancer burden is expected to drive the growth of the biomarker testing market in the coming years. Cancer comprises a group of diseases marked by the uncontrolled growth and spread of abnormal cells. This increasing burden is largely attributed to lifestyle-related risk factors such as unhealthy diets, smoking, physical inactivity, and excessive alcohol consumption. Biomarker testing plays a vital role in cancer detection by enabling early and accurate identification of disease-specific markers, thereby improving diagnostic precision. It also facilitates personalized treatment strategies, resulting in improved patient outcomes and more efficient healthcare management. For instance, in July 2024, the Australian Institute of Health and Welfare reported that 160,570 cancer cases were diagnosed in Australia in 2022, an increase of 3,789 cases from 156,781 in 2021. Therefore, the growing incidence of cancer is contributing significantly to the expansion of the biomarker testing market.
Major companies operating in the biomarker testing market are focusing on developing technologically advanced solutions, such as immunohistochemistry (IHC) technology, to enhance diagnostic accuracy, enable early disease detection, and support personalized treatment strategies. Immunohistochemistry (IHC) is a laboratory technique that utilizes antibodies to detect specific proteins in tissue samples, enabling the identification and visualization of biomarkers critical for disease diagnosis and research. For example, in July 2023, Quest Diagnostics Incorporated, a U.S.-based medical laboratory company, launched a new tissue-based prostate cancer biomarker test through its AmeriPath business. This test leverages proprietary biomarkers EV1, EV2, and EV3 to improve diagnostic precision by helping physicians more accurately identify and distinguish aggressive prostate cancer types. It addresses a critical clinical need by enhancing grading consistency and guiding appropriate, individualized treatment strategies.
In August 2025, Quanterix Corp., a U.S.-based life sciences company, acquired Emission Inc. for approximately $70 million. This acquisition is aimed at expanding Quanterix’s technology portfolio and market presence by incorporating Emission’s advanced multiplex and multi-omic assay technologies. The integration is expected to strengthen Quanterix’s position in the biomarker testing sector, enhance its diagnostic capabilities, and open new market opportunities. Emission Inc. is a U.S.-based biotechnology company specializing in multiplex and multi-omic assay solutions for biomarker testing.
Major players in the biomarker testing market are Roche Diagnostics International Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers AG, Becton Dickinson and Company, GE HealthCare Technologies Inc., Agilent Technologies Inc., Illumina Inc., Hologic Inc., Charles River Laboratories International Inc., PerkinElmer Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Myriad Genetics Inc., Guardant Health Inc., Sino Biological Inc., Proteome Sciences plc.
North America was the largest region in the biomarker testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in biomarker testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the biomarker testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Biomarker testing involves examining blood, tissue, or other bodily fluids to detect specific biological indicators that signify either normal or pathological conditions. This process is vital for disease diagnosis, monitoring disease progression, and creating personalized treatment strategies.
Biomarker testing includes several product types such as consumables, instruments, services, and more. Consumables refer to items that are used and depleted during procedures and must be replenished regularly, including medical supplies, food items, or office essentials. The primary technologies employed are polymerase chain reaction (PCR), next-generation sequencing (NGS), immunoassays, among others. It is widely used in fields such as oncology, cardiology, neurology, and infectious diseases, with key end-users including hospitals, diagnostic labs, research institutions, and other healthcare settings.
The biomarker testing market research report is one of a series of new reports that provides biomarker testing market statistics, including the biomarker testing industry global market size, regional shares, competitors with the biomarker testing market share, detailed biomarker testing market segments, market trends, and opportunities, and any further data you may need to thrive in the biomarker testing industry. These biomarker testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The biomarker testing market consists of revenues earned by entities by providing services such as clinical biomarker testing services, bioinformatics and data analysis services, sample collection and biobanking services, and companion diagnostic services. The market value includes the value of related goods sold by the service provider or included within the service offering. The biomarker testing market includes sales of analytical instruments, imaging devices, lab-on-a-chip and microfluidic devices, and data acquisition and integration hardware. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values generated by organizations in the specified geography within the market, irrespective of where they are produced. They do not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Biomarker Testing Market Characteristics3. Biomarker Testing Market Trends And Strategies4. Biomarker Testing Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Biomarker Testing Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Biomarker Testing Market34. Recent Developments In The Biomarker Testing Market
5. Global Biomarker Testing Growth Analysis And Strategic Analysis Framework
6. Biomarker Testing Market Segmentation
7. Biomarker Testing Market Regional And Country Analysis
8. Asia-Pacific Biomarker Testing Market
9. China Biomarker Testing Market
10. India Biomarker Testing Market
11. Japan Biomarker Testing Market
12. Australia Biomarker Testing Market
13. Indonesia Biomarker Testing Market
14. South Korea Biomarker Testing Market
15. Western Europe Biomarker Testing Market
16. UK Biomarker Testing Market
17. Germany Biomarker Testing Market
18. France Biomarker Testing Market
19. Italy Biomarker Testing Market
20. Spain Biomarker Testing Market
21. Eastern Europe Biomarker Testing Market
22. Russia Biomarker Testing Market
23. North America Biomarker Testing Market
24. USA Biomarker Testing Market
25. Canada Biomarker Testing Market
26. South America Biomarker Testing Market
27. Brazil Biomarker Testing Market
28. Middle East Biomarker Testing Market
29. Africa Biomarker Testing Market
30. Biomarker Testing Market Competitive Landscape And Company Profiles
31. Biomarker Testing Market Other Major And Innovative Companies
35. Biomarker Testing Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Biomarker Testing Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on biomarker testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for biomarker testing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biomarker testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product Type: Consumables; Instruments; Services2) By Technology: Polymerase Chain Reaction; Next-Generation Sequencing; Immunoassays; Other Technologies
3) By Application: Oncology; Cardiology; Neurology; Infectious Diseases; Other Applications
4) By End-User: Hospitals; Diagnostic Laboratories; Research Institutes; Other End-Users
Subsegments:
1) By Consumables: Reagents; Assay Kits; Sample Collection Devices; Chemicals And Buffers2) By Instruments: Polymerase Chain Reaction (PCR) Systems; Next-Generation Sequencing (NGS) Platforms; Microarray Systems; Mass Spectrometry Instruments; Immunoassay Analyzers
3) By Services: Biomarker Discovery Services; Diagnostic Testing Services; Companion Diagnostic Development; Clinical Trial Testing Services; Contract Research Organization (CRO) Services
Key Companies Profiled: Roche Diagnostics International Ltd.; Thermo Fisher Scientific Inc.; Abbott Laboratories; Danaher Corporation; Merck KGaA
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Roche Diagnostics International Ltd.
- Thermo Fisher Scientific Inc.
- Abbott Laboratories
- Danaher Corporation
- Merck KGaA
- Siemens Healthineers AG
- Becton Dickinson and Company
- GE HealthCare Technologies Inc.
- Agilent Technologies Inc.
- Illumina Inc.
- Hologic Inc.
- Charles River Laboratories International Inc.
- PerkinElmer Inc.
- Sysmex Corporation
- Bio-Rad Laboratories Inc.
- DiaSorin S.p.A.
- Myriad Genetics Inc.
- Guardant Health Inc.
- Sino Biological Inc.
- Proteome Sciences plc